Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Formononetin is a naturally occurring isoflavone, primarily found in red clover and the traditional Chinese medicinal herb Astragalus membranaceus. It belongs to the class of 7-hydroxyisoflavones, characterized by a methoxy group at position 4'. Formononetin exhibits a range of biological activities, including antioxidant, anti-inflammatory, anti-cancer, anti-apoptotic, antiviral, antibacterial, and estrogenic effects. Mechanistically, it modulates multiple cellular signaling pathways such as PI3K/AKT, MAPK/ERK/JNK (mitogen-activated protein kinase/extracellular signal-regulated kinase/c-Jun N-terminal kinase), STAT (signal transducer and activator of transcription), and nuclear factor kappa B (NF-κB). In cancer models it induces apoptosis via mitochondrial pathways involving Bax/Bcl-2/caspase-3 proteins and causes cell cycle arrest by regulating cyclins. In neurodegenerative disease models like Alzheimer’s disease it may inhibit amyloid-beta/RAGE interaction and reduce cytokine levels through modulation of Nrf2 signaling. Formononetin has been investigated in clinical trials for postmenopausal osteopenia[1][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on formononetin.